| Name | Title | Contact Details |
|---|
We are on the leading edge of research, development, clinical trials, and implementation of digital solutions that are aimed at harm reduction for various public health challenges. Our goal is to reduce harm and prevent unintentional deaths for people of all ages. Our team has pioneered apps that were developed in response to the opioid crisis, which is now a world-wide problem, as well as the COVID-19 pandemic and health & safety concerns in senior care centers.
At California Hospital Association (CHA), we collaborate with our members to provide strong and effective representation and advocacy to advance the interests of California hospitals, patients and communities. CHA is a trusted resource, working with members to achieve legislative, regulatory, and legal accomplishments at the state and federal level. Based in Sacramento, CHA is the statewide leader representing the interests of more than 400 hospitals and health systems in California.
PRONERVE is a Broomfield, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
South Carolina Heart Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Columbia, SC. To find more information about South Carolina Heart Center, please visit www.scheart.com
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.